ANALYSIS: With an Obermatt 360° View of 26 (better than 26% compared with alternatives), overall professional sentiment and financial characteristics for the stock Esperion Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Esperion Therapeutics. Only the consolidated Value Rank has an attractive rank of 84, which means that the share price of Esperion Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 84% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 43, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 15, meaning the company has a riskier financing structure than 85% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 72% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 28. ...read more